血液瘤中的PICALM-MLLT10融合基因:临床特征,当前实践和预后

Ji-Nuo Wang1,2,3, Bangcheng Ye1, Fei Cheng4

  • 1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

概括

在亚洲血性恶性瘤中,PICALM-MLLT10融合基因是罕见的. 被诊断出这种基因的患者,包括急性髓性白血病和急性淋巴细胞白血病,预后和生存率不佳.